Greenwich LifeSciences (NASDAQ:GLSI) Share Price Crosses Above 50 Day Moving Average on Disappointing Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) shares crossed above its fifty day moving average during trading on Tuesday following a better than expected earnings announcement. The stock has a fifty day moving average of $16.58 and traded as high as $19.28. Greenwich LifeSciences shares last traded at $18.70, with a volume of 1,109,181 shares trading hands.

The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.06).

Wall Street Analyst Weigh In

A number of research analysts recently commented on GLSI shares. HC Wainwright upped their price objective on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings lowered Greenwich LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $69.00.

Read Our Latest Research Report on GLSI

Institutional Trading of Greenwich LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ancora Advisors LLC boosted its stake in Greenwich LifeSciences by 101.2% during the third quarter. Ancora Advisors LLC now owns 21,610 shares of the company’s stock worth $390,000 after buying an additional 10,870 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Greenwich LifeSciences by 44.4% in the 3rd quarter. Goldman Sachs Group Inc. now owns 56,793 shares of the company’s stock valued at $1,025,000 after acquiring an additional 17,464 shares during the period. BlackRock Inc. acquired a new position in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $11,398,000. Deutsche Bank AG acquired a new position in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $126,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $1,124,000. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Stock Performance

The stock has a market cap of $274.52 million, a PE ratio of -12.14 and a beta of 1.57. The stock’s 50-day moving average is $16.58 and its two-hundred day moving average is $20.92.

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company developing immunotherapies intended to reduce the risk of breast cancer recurrence. The company’s work centers on GP2, an investigational peptide-based vaccine designed for patients with HER2/neu-positive breast cancer who have completed standard treatment. GP2 is intended to stimulate an immune response against cancer cells expressing HER2/neu and is administered with the immune-system stimulant GM-CSF. Greenwich LifeSciences is evaluating the candidate in clinical trials; it does not have an approved commercial product.

Further Reading

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.